Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.
Nat Commun. 2024 Nov 20;15(1):10062. doi: 10.1038/s41467-024-54404-w.
Test-negative designs (TNDs) are used to assess vaccine effectiveness (VE). Protection from infection-induced immunity may confound the association between case and vaccination status, but collecting reliable infection history can be challenging. If vaccinated individuals have less infection-induced protection than unvaccinated individuals, failure to account for infection history could underestimate VE, though the bias is not well understood. We simulated individual-level SARS-CoV-2 infection and COVID-19 vaccination histories and a TND. VE against symptomatic infection and VE against severe disease estimates unadjusted for infection history underestimated VE compared to estimates adjusted for infection history, and unadjusted estimates were more likely to be below 0%, which could lead to an incorrect interpretation that COVID-19 vaccines are harmful. TNDs assessing VE immediately following vaccine rollout introduced the largest bias and potential for negative VE against symptomatic infection. Despite the potential for bias, VE estimates from TNDs without prior infection information are useful because underestimation is rarely more than 8 percentage points.
测试阴性设计(TND)用于评估疫苗效力(VE)。感染诱导的免疫保护可能会混淆病例与疫苗接种状态之间的关联,但收集可靠的感染史可能具有挑战性。如果接种疫苗的个体比未接种疫苗的个体的感染诱导保护作用更低,那么如果不考虑感染史,VE 可能会被低估,尽管这种偏差还不太清楚。我们模拟了个体层面的 SARS-CoV-2 感染和 COVID-19 疫苗接种史,以及 TND。未调整感染史的症状感染 VE 和严重疾病 VE 估计值低于调整感染史的估计值,且未调整的估计值更有可能低于 0%,这可能导致错误的结论,即 COVID-19 疫苗是有害的。在疫苗推出后立即进行的 TND 评估会引入最大的偏差和对症状感染产生负 VE 的潜在风险。尽管存在偏差的可能性,但没有先前感染信息的 TND 提供的 VE 估计值仍然是有用的,因为低估通常不会超过 8 个百分点。